Since November 2014 nintedanib (trade name: Vargatef) has been approved in combination with docetaxel for the treatment of adults with advanced non-small cell lung cancer (NSCLC) of the glandular tissue (adenocarcinoma) who have already received chemotherapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.
According to the findings, there is an indication of a minor added benefit of nintedanib in combination with docetaxel in patients without brain metastases. However, in patients with brain metastases, the new drug has more disadvantages than chemotherapy with docetaxel alone. This results in a hint of a lesser benefit of nintedanib with the extent "considerable".
Findings from the only study are biased: at most indications can be derived
In its dossier the drug manufacturer compares treatment comprising nintedanib plus docetaxel with treatment comprising placebo plus docetaxel. As the treatment period in the nintedanib arm was longer than in the placebo arm (median: 4.3 versus 3 months), the observation periods for the study arms differed. Except for overall survival, the results are therefore uncertain for all outcomes.
In principle, at most an indication of an added benefit can be derived from the results of the only study included in the manufacturer dossier. As the analysis of the data shows, the advantages or disadvantages of nintedanib in combination with docetaxel primarily depend on whether patients already had brain metastases at the start of the study or not.
Patients without brain metastases live longer
Patients without brain metastases who received nintedanib in combination with docetaxel lived longer than study participants who were only treated with docetaxel (median: 13.5 versus 10.3 months). This results in an indication of a minor added benefit of nintedanib.
Although diarrhoea was more frequent in patients receiving nintedanib, this disadvantage does not challenge the survival advantage. Therefore, overall an indication remains of a minor added benefit for patients without brain metastases.
More symptoms in patients with brain metastases
If patients who already had brain metastases at the start of the study were treated with nintedanib, loss of appetite occurred more often and the symptoms nausea and vomiting, as well as diarrhoea, worsened during treatment. These disadvantages result in a hint of a lesser benefit of nintedanib in patients with brain metastases.
G-BA decides on the extent of added benefit
This dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of added benefit.
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website " http://ift.tt/1h8604z, published by IQWiG, provides easily understandable German-language information.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on " http://ift.tt/1lFNr7j). If you would like to be informed when these documents are available, please send an e-mail to " info@iqwig.de.
The G-BA website contains both general English-language information on the benefit assessment of new drugs pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of nintedanib.
Explore further: Sipuleucel-T in prostate cancer: Indication of added benefit
More information: http://ift.tt/1GP7g7B ertung-35a-SGB-V.pdf
Medical Xpress on facebook
Related Stories
Sipuleucel-T in prostate cancer: Indication of added benefit
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the ...
Open-angle glaucoma: Poor data for the fixed combination tafluprost/timolol
The fixed combination of the drugs tafluprost and timolol (trade name: Taptiqom) has been approved in Germany since December 2014 for adults with open-angle glaucoma or increased intraocular pressure (ocular hypertension). ...
Simoctocog alfa for haemophilia A: No suitable data
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Daclatasvir for hepatitis C: Hint of added benefit in genotype 4
Daclatasvir (trade name Daklinza) has been approved since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. According to the dossier assessment conducted by the German Institute for Quality ...
Vildagliptin for type 2 diabetes: No suitable data for combination with sulfonylurea
Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality ...
Recommended for you
Drug regulations tied to fewer prescriptions of effective gout drug
Well intentioned, but costly and potentially problematic. That's how researchers describe the end result of a decision by the Food and Drug Administration (FDA) to regulate colchicine, a drug used to treat gout, among other ...
Biostatistician helps FDA approve first biosimilar drug
Bernard "Chip" Cole got the call in late December. The U.S. Food and Drug Administration summoned the University of Vermont biostatistician for another mission. Since 2013, Cole has sat on an important FDA ...
Mylan offers about $29B for rival generic drugmaker Perrigo
In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion.
Pharmacist survey raises concerns for patient access to generic drugs
Patient access to generic prescription drugs and community pharmacies are both increasingly at risk due to inadequate reimbursement rates that fail to cover the cost of filling prescriptions, according to a new survey of ...
Combining nortriptyline and morphine provides better pain relief than using either drug alone
The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.
Cost of cancer drugs varies widely based on who's paying
Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Since November 2014 nintedanib (trade name: Vargatef) has been approved in combination with docetaxel for the treatment of adults with advanced non-small cell lung cancer (NSCLC) of the glandular tissue (adenocarcinoma) who have already received chemotherapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.
According to the findings, there is an indication of a minor added benefit of nintedanib in combination with docetaxel in patients without brain metastases. However, in patients with brain metastases, the new drug has more disadvantages than chemotherapy with docetaxel alone. This results in a hint of a lesser benefit of nintedanib with the extent "considerable".
Findings from the only study are biased: at most indications can be derived
In its dossier the drug manufacturer compares treatment comprising nintedanib plus docetaxel with treatment comprising placebo plus docetaxel. As the treatment period in the nintedanib arm was longer than in the placebo arm (median: 4.3 versus 3 months), the observation periods for the study arms differed. Except for overall survival, the results are therefore uncertain for all outcomes.
In principle, at most an indication of an added benefit can be derived from the results of the only study included in the manufacturer dossier. As the analysis of the data shows, the advantages or disadvantages of nintedanib in combination with docetaxel primarily depend on whether patients already had brain metastases at the start of the study or not.
Patients without brain metastases live longer
Patients without brain metastases who received nintedanib in combination with docetaxel lived longer than study participants who were only treated with docetaxel (median: 13.5 versus 10.3 months). This results in an indication of a minor added benefit of nintedanib.
Although diarrhoea was more frequent in patients receiving nintedanib, this disadvantage does not challenge the survival advantage. Therefore, overall an indication remains of a minor added benefit for patients without brain metastases.
More symptoms in patients with brain metastases
If patients who already had brain metastases at the start of the study were treated with nintedanib, loss of appetite occurred more often and the symptoms nausea and vomiting, as well as diarrhoea, worsened during treatment. These disadvantages result in a hint of a lesser benefit of nintedanib in patients with brain metastases.
G-BA decides on the extent of added benefit
This dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of added benefit.
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website " http://ift.tt/1h8604z, published by IQWiG, provides easily understandable German-language information.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on " http://ift.tt/1lFNr7j). If you would like to be informed when these documents are available, please send an e-mail to " info@iqwig.de.
The G-BA website contains both general English-language information on the benefit assessment of new drugs pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of nintedanib.
Explore further: Sipuleucel-T in prostate cancer: Indication of added benefit
More information: http://ift.tt/1GP7g7B ertung-35a-SGB-V.pdf
Medical Xpress on facebook
Related Stories
Sipuleucel-T in prostate cancer: Indication of added benefit
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the ...
Open-angle glaucoma: Poor data for the fixed combination tafluprost/timolol
The fixed combination of the drugs tafluprost and timolol (trade name: Taptiqom) has been approved in Germany since December 2014 for adults with open-angle glaucoma or increased intraocular pressure (ocular hypertension). ...
Simoctocog alfa for haemophilia A: No suitable data
Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Daclatasvir for hepatitis C: Hint of added benefit in genotype 4
Daclatasvir (trade name Daklinza) has been approved since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. According to the dossier assessment conducted by the German Institute for Quality ...
Vildagliptin for type 2 diabetes: No suitable data for combination with sulfonylurea
Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality ...
Recommended for you
Drug regulations tied to fewer prescriptions of effective gout drug
Well intentioned, but costly and potentially problematic. That's how researchers describe the end result of a decision by the Food and Drug Administration (FDA) to regulate colchicine, a drug used to treat gout, among other ...
Biostatistician helps FDA approve first biosimilar drug
Bernard "Chip" Cole got the call in late December. The U.S. Food and Drug Administration summoned the University of Vermont biostatistician for another mission. Since 2013, Cole has sat on an important FDA ...
Mylan offers about $29B for rival generic drugmaker Perrigo
In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion.
Pharmacist survey raises concerns for patient access to generic drugs
Patient access to generic prescription drugs and community pharmacies are both increasingly at risk due to inadequate reimbursement rates that fail to cover the cost of filling prescriptions, according to a new survey of ...
Combining nortriptyline and morphine provides better pain relief than using either drug alone
The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.
Cost of cancer drugs varies widely based on who's paying
Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment